Hospira Injection Recall Issued Due to Particulate Matter

One lot of Hospira’s sodium chloride injection has been recalled following a consumer complaint of particulate matter, which could pose serious and potentially life-threatening heath risks.  

A Hospira .09%Sodium Chloride Injection recall was announced by the FDA on April 26, after four different contaminants were identified within the injection solutions following testing of four individual containers.

The Hospira injection contamination that was identified within the fluid consisted of polyester fiber, nylon fiber, cotton fiber, and nitrocellulose fiber.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The injections were originally recalled in August 2012, and this notice was a re-announcement of the action. However, Hospira Inc. has not received any reports of adverse consequences reported in relation to the solutions.

The recall consists of .09% Sodium Chloride Injection 100 ml in flexible containers with lot number 05-201-JT. The recalled fluids were manufactured by Hospira Inc. and have an expiration date of May 1, 2013. The product was distributed to the following states to wholesalers, distributors, hospitals, and pharmacies: Alaska, Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Iowa, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Michigan, Missouri, Mississippi, North Carolina, North Dakota, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin, West Virginia and Wyoming

Use of the contaminated fluids may cause several health consequences such as local inflammation, phlebitis, or weakened immune systems. The risk to the consumer is heightened if the bacteria travels throughout the body and causes inflammation in the lungs.

Consumers have been advised to stop using and distributing the product immediately and contact Stericycle at 1-888-597-9582 where they will inform the consumer to quarantine any remaining inventory until they can arrangement to remove and replace the product.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

EU Launches Investigation Into Ozempic Vision Loss Problems
EU Launches Investigation Into Ozempic Vision Loss Problems (Posted yesterday)

Following nearly 20 reports of vision problems from Ozempic or Wegovy since a study was published in July 2024, Danish health officials are calling for an EU investigation into the safety of semaglutide-based drugs.